drugset / Trial / NCT00936429

Study of HBV-001 D1 in Healthy Adults

NCT00936429

Phase 1 Completed 16 enrolled Hawaii Biotech, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a single-center, double-blind, randomized, Phase 1 study to assess the safety and tolerability of HBV-001 D1 in healthy adult subjects.

Timeline

Start
2009-07
Primary completion
2010-07
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DEN1-80E Vaccine 10 ug Intramuscular
Subject DEN1-80E Vaccine 50 ug Intramuscular
Background Aluminum hydroxide Unknown 3.5 mg Intramuscular

Indications